1. Treatment Pathways and Associated Costs of Advanced or Metastatic ALK＋ Non-Small Cell Lung Cancer in Greece
- Author
-
Ioannis Boukovinas, Dimitrios Krikelis, P. Makrantonakis, Georgios Koumakis, Konstantinos N. Syrigos, Hara Kousoulakou, Paraskevas Kosmidis, Argyro Markouri, M Geitona, Epaminondas Samantas, and V. Georgoulias
- Subjects
Oncology ,Chemotherapy ,medicine.medical_specialty ,Palliative care ,Ceritinib ,Crizotinib ,business.industry ,Total cost ,030503 health policy & services ,medicine.medical_treatment ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Anaplastic lymphoma kinase ,030212 general & internal medicine ,Non small cell ,0305 other medical science ,business ,Lung cancer ,medicine.drug - Abstract
Objective: To investigate the resource use and costs associated with the management of metastatic anaplastic lymphoma kinase inhibitors (ALK+) NSCLC in Greece. Methods: The resource use was based on the outcomes of a Delphi panel with seven oncologists and unit costs derived from officially published sources. Results: The average per patient cost in the current treatment pathway (chemotherapy, crizotinib, chemotherapy, palliative care) was estimated at €67,391. The average per patient cost in future scenario 1 (crizotinib, ceritinib, chemotherapy, palliative care) was estimated at €104,571 (treatment duration 26 months) while in future scenario 2 (chemotherapy, ceritinib, chemotherapy, palliative care) was estimated at €134,215 (treatment duration 29.3 months). Conclusion: Ceritinib as second line treatment leads to an increase in total costs reflecting the longer survival
- Published
- 2016